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Neurometabolic disorder is one of the important groups of diseases that 
prominently has presentation early infantile period. In this study, we evaluated 
the result of metabolic screening of the patient with seizure, developmental delay 
and/or regression in development, demographic disease clinical and radiological 
findings on admitted and outpatient visited children.
Materials & Methods
Two-year retrospective review of 187 children with seizure, developmental 
delay and/or regression in the Mofid Children Hospital, Tehran, Iran was 
performed. The diagnosis was based on observation, findings of EEG and history 
of the patient, besides evaluation of patient milestones. The result of metabolic 
screening with Tandem mass spectrometry was evaluated using SPSS (ver.18.0) 
Statistical software.
Results
Totally, 187 children with seizure, regression and/or developmental delay were 
evaluated by metabolic screening with tandem mass spectrometry method. The 
results of laboratory examination had no relationship between positive results of 
metabolic screening and the mentioned disease. The relations between positive 
results of metabolic screening and seizure, regression and/or developmental 
delay were not statistically meaningful.
Conclusion
Positive results of metabolic screening and seizure, regression and/or developmental 
delay were not statistically meaningful.
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Introduction 
Metabolic diseases are a group of diseases characterized by impaired function of 
an enzyme or vitamin necessary for the chemical reaction in the body. Enzyme 
deficiency leads to a lack of essential substances in the brain and a variety of 
metabolic diseases. Screening and identification of metabolic diseases, enzyme 
disorders, and newborn screening is a global necessity. Early detection and 
diagnosis of certain genetic, metabolic or congenital diseases can lead to a 
significant reduction in mortality and associated disabilities (1-10).
Although inborn errors of metabolic diseases are rare but recurrent seizure is a 
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criteria included patient dissatisfaction, proof of 
diagnosis other than developmental delay, seizures and 
developmental regression.
Findings were recorded using questionnaires, patient 
information including gender, age, family history of 
similar disease, the presence of family kinship, and 
metabolic screening.
The clinical manifestations were recorded including the 
early onset presentations and the signs and symptoms 
presented during the time of admission. The laboratory 
studies were all rechecked.
The result of metabolic screening with Tandem mass 
spectrometry was evaluated using SPSS (ver. 18.0) 
(Chicago, IL, USA) Statistical software.
Results
Totally, 187 patients with seizure, developmental delay 
and/or regression were enrolled. The mean (SD) age 
of the patients was 40.93 (31.95) month, 118 patients 
(63.1%) of the children studied were male and 67 
(36.9%) were female. Ten (5.35%) of the children 
surveyed had positive test results for metabolic 
screening.
Two children with type 1 glutaric aciduria were found. 
One of them was 6-month-old girl who presented 
with seizure and another was a 5-month-old boy with 
dystonia, seizures, developmental delay, and family 
history of type 1 glutaric aciduria. Both cases were 
confirmed by urine organic acid test.
Two children were diagnosed as methylmalonic 
acidemia (MMA). One of them was 12-month-old boy 
who manifested with regression and developmental 
delay and another was 9-month-old boy with seizures, 
developmental delay, and regression.
An 11-year-old girl with Carnitine Transporter 
Deficiency presented with seizures and moderate 
developmental delay in motor and speech domain. A 
13-yr-old boy with seizures and moderate developmental 
delay with Primary Carnitine Deficiency was found. 
A 4.5-month-old boy with developmental delay was 
diagnosed as propionic acidemia. A 10-yr-old girl with 
seizures and developmental regression had Isovaleric 
Acidemia confirmed with investigation of urine organic 
acids. A 4.5-month-old girl was reported of positive 
test for homocystinuria and MMA. She was referred 
common symptom of these disorders and in some 
resistant epileptic patients, without treatment of the 
underlying disease, the seizures are uncontrollable (7, 
8, 11).
Metabolic disorders are not immediately symptomatic 
at birth and can manifest with slowly progressive 
encephalopathy. Nutritional problems, lethargy, 
vomiting, jaundice, developmental delay, sleep apnea, 
tachypnea, hypertonicity, ataxia, motion sickness, 
seizures or coma can be seen (2, 6, 8, 11, 12).
Regarding children of seizures, metabolic diseases 
must be considered as follows:
1. History of parental consanguinity, family history of 
similar disease that begins in infancy or regression of 
psychomotor
2. Myoclonus, and tonic spasms, unexplained persistent 
seizures or seizures linked to meals
3. Companionship with neurological deterioration or 
systemic symptoms
4. Early and progressive myoclonic epilepsy and 
seizures get worse with certain anticonvulsant drugs 
such as sodium valproate
5. EEG patterns such as burst suppression, high voltage 
and slow rhythmic delta waves with myoclonus and 
Paroxysms seen in the photic stimulation (5, 8, 13).
In this study, we tried to evaluate the result of metabolic 
screening of the patients with seizure, developmental 
delay and/or regression in development, demographic 
disease clinical and radiological findings in admitted 
and outpatient visited children in Mofid Children 
Hospital, Tehran, Iran from 2013-2015.
Materials & Methods
From Mar 2013 to Mar 2015, 187 patients with 
seizure, developmental delay and/or regression in the 
Mofid Children Hospital, Tehran, Iran were evaluated. 
The diagnosis was based on observation, findings 
of EEG and history of the patient, and evaluation of 
patient milestones. The data were classified in a chart 
questionnaire. The data were recorded confidentially 
and informed consent was obtained from parents. Each 
person was characterized by a numerical code.
Inclusion criteria included children with developmental 
delay, unusual seizures and regression that undergo 
mass spectrometry for metabolic screening. Exclusion 
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1). None of the patients’ clinical characteristics was 
significantly associated with screening test result. None 
of the patients’ clinical characteristics was significantly 
associated with Consanguinity of parents (Table 2). 
None of the patients’ clinical characteristics was 
significantly associated with Positive family history 
(Table 3). None of the patients’ clinical characteristics 
was significantly associated with abnormal MRI (Table 
4).
due to seizure and developmental delay. The patient’s 
mother had a history of homocysteinemia.
An 8-yr-old girl with seizures, developmental delay, 
and regression underwent metabolic screening. The 
laboratory report raised the possibility of MMA, not 
confirmed by urine organic acid test. Therefore, in all 
analyses to examine the association between metabolic 
screening test results with clinical characteristics, 
positive result was confirmed in 9 children (Table 
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Table 1. Relationship between metabolic screening test results with clinical characteristics of the studied children
Total






YES 143 8(5.6) 135(94.4)
0.67
NO 48 4(8.3) 44(91.7)
Developmental
regression
YES 137 5(3.6) 132(96.4)
0.24
NO 32 0(0) 32(100)
Speech Developmental
Delay
YES 135 8(5.9) 127(94.2)
0.36




YES 137 9(6.6) 128(93.4)
0.21
NO 39 0(0) 39(100)








Yes 136 73(81.1) 63(75.9)
0.4
No 37 17(18.9) 20(24.1)
Developmental
regression
Yes 43 22(23.9) 21(25.6)
0.8
No 131 70(76.1) 61(74.4)
Speech Developmental
Delay
Yes 124 66(76.7) 58(82.9)
0.35




Yes 126 65(73) 61(80.3)
0.28
No 39 24(27) 15(19.7)
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Yes 134 49(83.1) 85(75.9)
0.28
No 37 10(16.9) 27(24.1)
Developmental
regression
Yes 43 13(21.7) 30(28.8)
0.46
No 129 47(78.3) 82(73.2)
Speech Developmental
Delay
Yes 123 40(74.1) 83(83)
0.19




Yes 125 43(74.1) 82(78.1)
0.56
No 38 15(25.9) 23(21.9)






Yes 117 60(80) 57(81.4)
0.82
No 28 15(20) 13(18.6
Developmental
regression
Yes 36 17(22.4) 19(27.1)
0.5
No 110 59(77.6) 51(72.9)
Speech Developmental
Delay
Yes 108 53(75.7) 55(87.3)
0.08




Yes 107 52(72.2) 55(82.1)
0.17
No 32 20(28.8) 12(17.9)
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Discussion
Our study is the first one, which is reviewing results 
of metabolic screening of the patients with seizures, 
developmental delay and/or regression. In this 
screening, about 20 metabolic diseases were evaluated. 
Before our study, few case reports had been reported 
(4-6).
The mean age of the patients in our study was 40.93 
months, which was consistent with previous studies (4-
6).
In this study from 143 patients who had seizures (often 
refractory and early onset), 8 (5.6%) had abnormal 
metabolic screening test results, of course, this result 
was not statistically meaningful (P=0.4) and less than 
previous studies (4, 5, 10). This difference may be 
attributed to the type of metabolic screening tests in 
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